Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells

Cancer Biology and Therapy

Volumn 6, Issue 5, 2007, Pages 697-704

  Liu, Hongyun ^d   Guo, Songchuan ^a   Roll, Richard ^a   Li, Jie ^f   Diao, Zhijuan ^d   Shao, Ningsheng ^f   Riley, Mark R ^g   Cole, Alexander M ^e   Robinson, J Paul ^b,c   Snead, Nicholas M ^b   Shen, Guanxin ^d   Guo, Peixuan ^a,b,h  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNIVERSITY OF CENTRAL FLORIDA   (United States)

^f INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^g UNIVERSITY OF ARIZONA   (United States)

^h Purdue University   (United States)

Author keywords

Bacteriophage phi29; Gene therapy; Nanomotor; pRNA; Ribozyme

Indexed keywords

HAMMERHEAD RIBOZYME; MESSENGER RNA; SURVIVIN;

ARTICLE; BACTERIOPHAGE; BREAST CANCER; CANCER CELL; CELL DEATH; CYTOTOXICITY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MULTIPLE CANCER; NASOPHARYNX CANCER; PROSTATE CANCER; UTERINE CERVIX CANCER;

EID: 34548219458     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.5.3962     Document Type: Article

References (54)

1. Forster AC, Symons RH. Self-cleavage of virusoid RNA is performed by the proposed 55- nucleotide active site. Cell 1987; 50:9-16.
2. Sarver NA, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247:1222-5.
3. Chowrira BM, Berzal-Herranz A, Burke JM. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature 1991; 354:320-2.
4. Coleman J, Hirashima A, Inocuchi Y, Green PJ, Inouye M. A novel immune system against bacteriophage infection using complementary RNA (micRNA). Nature 1985; 315:601-3.
5. Knecht DA, Loomis WF. Antisense RNA inactivation of myosin heavy chain gene expres-sion in Dictyostelium discoideum. Science 1987; 236:1081-6.
6. Li H, Li WX, Ding SW. Induction and suppression of RNA silencing by an animal virus. Science 2002; 296:1319-21.
7. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-3.
8. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418:435-8.
9. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9.
10. Carmichael GG. Medicine: Silencing viruses with RNA. Nature 2002; 418:379-80.
11. Couzin J. Breakthrough of the year: Small RNAs make big splash. Science 2002; 298:2296-7.
12. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13:644-70.
13. Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh V, Douglas JT, Curiel DT. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 2003; 309:282-93.
14. Papiewska-Pajak I, Antoszczyk S. Regulation of beta1 integrin expression in endothelial cells by chimeric tRNA(Val) ribozyme. Acta Biochim Pol 2006; 53:311-6.
15. Chang Z, Westaway S, Li S, Zaia JA, Rossi JJ, Scherer LJ. Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters. Mol Ther 2002; 6:481-9.
16. Westaway SK, Larson GP, Li S, Zaia JA, Rossi JJ. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp Ser 1995; 194-9.
17. Cotten M, Birnstiel ML. Ribozyme mediated destruction of RNA in vivo. EMBO J 1989; 8:3861-6.
18. Guo P, Erickson S, Anderson D. A small viral RNA is required for in vitro packaging of bacteriophage f29 DNA. Science 1987; 236:690-4.
19. Guo P, Zhang C, Chen C, Trottier M, Garver K. Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell 1998; 2:149-55.
20. Zhang F, Lemieux S, Wu X, St.-Arnaud S, McMurray CT, Major F, Anderson D. Function of hexameric RNA in packaging of bacteriophage phi29 DNA in vitro. Mol Cell 1998; 2:141-7.
21. Guo P. Structure and function of phi29 hexameric RNA that drive viral dna packaging motor: Review. Prog in Nucl Acid Res and Mole Biol 2002; 72:415-72.
22. Guo P. Bacterial virus phi29 DNA-packaging motor and its potential applications in gene therapy and nanotechnology. Methods Mol Biol 2005; 300:285-324.
23. Zhang CL, Lee CS, Guo P. The proximate 5′ and 3′ ends of the 120-base viral RNA (pRNA) are crucial for the packaging of bacteriophage f29 DNA. Virology 1994; 201:77-85.
24. Hoeprich S, ZHou Q, Guo S, Qi G, Wang Y, Guo P. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther 2003; 10:1258-67.
25. Chen C, Zhang C, Guo P. Sequence requirement for hand-in-hand interaction in formation of pRNA dimers and hexamers to gear phi29 DNA translocation motor. RNA 1999; 5:805-18.
26. Shu D, Huang L, Hoeprich S, Guo P. Construction of phi29 DNA-packaging RNA (pRNA) monomers, dimers and trimers with variable sizes and shapes as potential parts for nano-devices. J Nanosci and Nanotech (JNN) 2003; 3:295-302.
27. Hoeprich S, Guo P. Computer modeling of three-dimensional structure of DNA-packaging RNA(pRNA) monomer, dimer, and hexamer of phi29 DNA packaging motor. J Biol Chem 2002; 277:20794-803.
28. Garver K, Guo P. Boundary of pRNA functional domains and minimum pRNA sequence requirement for specific connector binding and DNA packaging of phage phi29. RNA 1997; 3:1068-79.
29. Zhang C, Trottier M, Chen C, Guo P. Chemical modification patterns of active and inactive as well as procapsid-bound and unbound DNA-packaging RNAof bacterial virus Phi29. Virology 2001; 281:281-93.
30. Trottier M, Mat-Arip Y, Zhang C, Chen C, Sheng S, Shao Z, Guo P. Probing the structure of monomers and dimers of the bacterial virus phi29 hexamer RNA complex by chemical modification. RNA 2000; 6:1257-66.
31. Mat-Arip Y, Garver K, Chen C, Sheng S, Shao Z, Guo P. Three-dimensional interaction of Phi29 pRNA dimer probed by chemical modification interference, cryo-AFM, and cross-linking. J Biol Chem 2001; 276:32575-84.
32. Zhang CL, Tellinghuisen T, Guo P. Confirmation of the helical structure of the 5′/3′ termini of the essential DNA packaging pRNA of phage f29. RNA 1995; 1:1041-50.
33. Zhang CL, Tellinghuisen T, Guo P. Use of circular permutation to assess six bulges and four loops of DNA-packaging pRNA of bacteriophage f29. RNA 1997; 3:315-22.
34. Wichitwechkarn J, Johnson D, Anderson D. Mutant prohead RNAs in the in vitro packaging of bacteriophage phi 29 DNA-gp3. J Mol Biol 1992; 223:991-8.
35. Reid RJD, Zhang F, Benson S, Anderson D. Probing the structure of bacteriophage f29 prohead RNA with specific mutations. J Biol Chem 1994; 269:18656-61.
36. Reid RJD, Bodley JW, Anderson D. Characterization of the prohead-pRNA interaction of bacteriophage f29. J Biol Chem 1994; 269:5157-62.
37. Chen C, Guo P. Magnesium-induced conformational change of packaging RNA for procapsid recognition and binding during phage phi29 DNA encapsidation. J Virol 1997; 71:495-500.
38. Zhang CL, Garver K, Guo P. Inhibition of phage f29 assembly by antisense oligonucleotides targeting viral pRNA essential for DNA packaging. Virology 1995; 211:568-76.
39. Trottier M, Garver K, Zhang C, Guo P. DNA-packaging pRNA as target for complete inhibition of viral assembly in vitro and in vivo. Nucleic Acids Symposium Series 1997; 36:187-9.
40. Trottier M, Guo P. Approaches to determine stoichiometry of viral assembly components. J Virol 1997; 71:487-94.
41. Trottier M, Zhang CL, Guo P. Complete inhibition of virion assembly in vivo with mutant pRNA essential for phage f29 DNA packaging. J Virol 1996; 70:55-61.
42. Chen C, Sheng S, Shao Z, Guo P. A dimer as a building block in assembling RNA: A hexamer that gears bacterial virus phi29 DNA-translocating machinery. J Biol Chem 2000; 275:17510-6.
43. Shu D, Moll D, Deng Z, Mao C, Guo P. Bottom-up assembly of RNA arrays and super-structures as potential parts in nanotechnology. Nano Letters 2004; 4:1717-24.
44. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Human Gene Therapy 2005; 16:1097-109.
45. Guo S, Huang F, Guo P. Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther 2006; 13:814-20.
46. Khaled A, Guo S, Li F, Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Letters 2005; 5:1797-808.
47. Weikert S, Schrader M, Muller M, Schulze W, Krause H, Miller K. Expression levels of the inhibitor of apoptosis survivin in testes of patients with normal spermatogenesis and spermatogenic failure. Fertil Steril 2005; 1:1100-5).
48. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci 2001; 98:635-40.
49. Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002; 109:285-6.
50. Zhang CL, Trottier M, Guo PX. Circularly permuted viral pRNA active and specific in the packaging of bacteriophage f29 DNA. Virology 1995; 207:442-51.
51. Zhang YJ, Wang XP, Deng JH, Salinas RA, Oishi N, Gao SJ. Suppression of oncogenic viral interferon regulatory factor (vIRF) of Kaposi's sarcoma-associated herpesvirus by ribozyme-mediated cleavage. Cancer Gene Ther 2001; 8:285-93.
52. Goldsby RA, Kindt TJ, Osborne BA, Kuby J. Antigens: Immunology. New York: W. H. Freeman and Company, 2002:57-61.
53. Shu D, Zhang H, Jin J, Guo P. Counting of six pRNAs of phi2q DNA-packaging motor with customized single-molecule dual-view system. EMBO J 2007; 26:527-37.
54. Guo P, Lee T. Viral nanomotors for packaging of ds DNA and dsRNA. Mol Microbio. 2007 (In Press).